Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 1,575 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Erythromelalgia
Interventions: Amitriptyline Hydrochloride, Placebo; Drug
Lead sponsor: AlgoTherapeutix; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Stroke
Interventions: occupational therapy task-oriented approach, Forearm rotation orthosis, No treatment; Behavioral · Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diffuse Large B-cell Lymphoma
Interventions: RAD001, LBH589, Doublet (RAD001 and LBH589); Drug
Lead sponsor: Anne Beaven, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diffuse Intrinsic Pontine Glioma, Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: K27M peptide, Nivolumab; Biological · Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 3 Years to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 14
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 11 more

Conditions: Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
Interventions: Bridging radiotherapy (BRT), Conditioning chemotherapy, CAR T-cell product; Radiation · Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Interventions: Switch to E/C/FTC/TAF daily; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Naltrexone, Methylphenidate Abuse
Interventions: Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421; Drug
Lead sponsor: Avekshan LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteers
Interventions: AZD9291; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: THALASSEMIA MAJOR
Interventions: Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI; Other
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 12 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Obesity
Interventions: CagriSema (cagrilintide B and semaglutide I), CagriSema A; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Addiction, Opioid
Interventions: Enhanced Monitoring and Feedback (EMF), NIATx/MAT Academy, NIATx-Internal Facilitation (NIATx-IF), NIATx-External Facilitation (NIATx-EF); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Olympia, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 36
States / cities: Long Beach, California • Pasadena, California • Denver, Colorado + 32 more

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions: Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension, Female Sexual Dysfunction
Interventions: nebivolol and metoprolol succinate, metoprolol succinate and nebivolol; Drug
Lead sponsor: East Coast Institute for Research; Network
Eligibility: 40 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Healthy Volunteers
Interventions: TAK-988, TAK-988 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Glendale, California • Millcreek, Utah

Conditions: Carcinoma, Non Small Cell Lung
Interventions: CT Perfusion; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Breastfeeding
Interventions: LC and Electronic Prompt; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 299 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lung Cancer, Adenocarcinoma
Interventions: Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase II - GM.CD40L.CCL21 Vaccinations; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Opioid Use, Opioid-use Disorder, Substance Use Disorders
Interventions: Sky Intervention; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Traumatic Brain Injury, Post-concussive Syndrome
Interventions: Sildenafil; Drug
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Opioid Use Disorder
Interventions: Mobile phone-assisted intervention, Peer navigator, Standard of care referral for out-patient MAT; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions: Ublituximab, Lenalidomide; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Huntsville, Alabama • Bethesda, Maryland

Conditions: Achievement
Interventions: Family Check-Up; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: Not listed
Enrollment: 848 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Eugene, Oregon

Search by objective public record fields.

EASE (Efficacy of ATX01 Study in Erythromelalgia)

Forearm Rotation Orthosis for Stroke

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

Study for Naltrexone on the Abuse Potential of Methylphenidate

To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.

Reproductive Capacity and Iron Burden in Thalassemia

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

Stagewise Implementation-To-Target- Medications for Addiction Treatment (SITT-MAT)

A New Oral Treatment For Type II Diabetes Mellitus

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Computed Tomography (CT) Perfusion Imaging of Lung Cancer

Provider Approaches to Improved Rates of Infant Nutrition and Growth Study

Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

Evaluating The Efficacy Of A Mind-Body Intervention In Overcoming Opioid Addiction

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.

Peer-led, Mobile App Supported Linkage to Opioid Use Disorder Treatment

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

The Positive Family Support Project - Partnering With Families for a Successful Transition to School